These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27394934)

  • 1. National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
    Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
    Drug Alcohol Depend; 2016 Sep; 166():254-7. PubMed ID: 27394934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
    Morley KC; Logge W; Pearson SA; Baillie A; Haber PS
    J Subst Abuse Treat; 2017 Mar; 74():23-25. PubMed ID: 28132696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pharmacotherapies for alcohol dependence.
    Graham R; Wodak AD; Whelan G
    Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
    Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
    Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of healthcare utilization among patients treated with alcoholism medications.
    Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
    Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
    Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
    Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
    Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
    Mason BJ
    J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study.
    Thompson A; Ashcroft DM; Owens L; van Staa TP; Pirmohamed M
    PLoS One; 2017; 12(3):e0173272. PubMed ID: 28319159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Kranzler HR; Van Kirk J
    Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
    Mason BJ
    Eur Neuropsychopharmacol; 2003 Dec; 13(6):469-75. PubMed ID: 14636963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
    Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
    Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.
    Basu D; Jhirwal OP; Mattoo SK
    Am J Addict; 2005; 14(4):381-95. PubMed ID: 16188718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
    Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
    Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.